[Contraception for women after 40: CNGOF Contraception Guidelines]

Gynecol Obstet Fertil Senol. 2018 Dec;46(12):865-872. doi: 10.1016/j.gofs.2018.10.008. Epub 2018 Nov 10.
[Article in French]

Abstract

Introduction: Choosing contraception for women over 40 can be sometimes difficult but it is crucial since fertility and pregnancy's risks still exist. It requires a thorough evaluation of the situation, in order to identify any vascular and metabolic risk factors, along with the uterine and mammary benign pathologies already diagnosed.

Objective: The objective of this review was to elaborate some guidelines for clinical practice regarding contraception's prescription for women over 40.

Methods: A systematic review of the French and English existing literature was conducted. Pubmed and the Cochrane library were used to identify studies about contraception for perimenopausal women. International guidelines published by scientific societies were also reviewed (RCOG, FSRH, ESHRE, ACOG, WHO, HAS).

Results: No contraceptive methods are contraindicated on the sole basis of age alone. However, because age is a risk factor for vascular and metabolic diseases, combined hormonal contraception and DMPA should not be prescribed at first intention. Copper IUD and progestin-only contraceptives (pill, implant, intrauterine device) should primarily be considered, since they offer good efficacy with lower risks.

Conclusions: Contraception for women over 40 should not be put aside. Long acting reversible contraception and progestin-only pill have to be prescribed as first-ine. Contraception is no longer needed for women over 50 who use non-hormonal contraception, after a 12 month-amenorrhea. Patients treated with combined hormonal contraception must stop using it over 50. Measuring hormonal levels while using hormonal contraception is not recommended. An hormonal-contraception-free interval must be considered, while using barrier contraception method. If an ovarian activity persists, a non-hormonal contraception or progestin-only contraception (except for DMPA) should be (re-)established.

Keywords: Contraception; Contraception hormonale; Dispositif intra-utérin; Femmes de plus de 40 ans; Hormonal contraceptive; Intrauterine device; Perimenopause; Progestatif; Progestin-only contraceptive; Périménopause; Women over 40.

Publication types

  • Practice Guideline
  • Systematic Review

MeSH terms

  • Adult
  • Age Factors
  • Contraception / adverse effects*
  • Contraception / methods*
  • Contraceptives, Oral, Combined
  • Contraceptives, Oral, Hormonal
  • Drug Implants
  • Female
  • Fertility
  • France
  • Humans
  • Intrauterine Devices, Copper
  • Metabolic Diseases
  • Perimenopause*
  • Pregnancy
  • Progestins / administration & dosage
  • Risk Factors
  • Vascular Diseases

Substances

  • Contraceptives, Oral, Combined
  • Contraceptives, Oral, Hormonal
  • Drug Implants
  • Progestins